New York, September 15, 2025 — Leads & Copy — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, highlighted the successful commercial launch of Ryoncil® (remestemcel-L-rknd) at the Morgan Stanley and Cantor Fitzgerald Annual Global Healthcare Conferences in New York this past week. Ryoncil® is the only mesenchymal stromal cell (MSC) product approved by the United States Food and Drug Administration (FDA).
Mesoblast Chief Executive Silviu Itescu reiterated the strong first quarter launch of Ryoncil® and product sales in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD), as reported in the Company’s full year earnings. He also discussed plans to onboard new sites and increase product usage.
Dr. Itescu highlighted plans for expanding Ryoncil® into additional indications, including adult SR-aGvHD and inflammatory bowel disease (IBD), and key Phase 3 milestones for its second-generation product Rexlemestrocel-L.
Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company’s therapies utilize a proprietary mesenchymal lineage cell therapy technology platform that responds to severe inflammation by releasing anti-inflammatory factors.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell (MSC) therapy for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. The Company has established commercial partnerships in Japan, Europe and China.
For media inquiries, Emma Neal of Allison Worldwide can be reached at +1 603 545 4843 or emma.neal@allisonworldwide.com.
Source: Mesoblast
